Literature DB >> 27271956

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment.

L Nosotti1, A Petrelli2, D Genovese3, S Catone3, C Argentini3, S Vella3, A Rossi2, G Costanzo2, A Fortino2, L Chessa4, L Miglioresi2, C Mirisola2.   

Abstract

Aims of the study are to investigate, in a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome. 365 patients with HCV infection were observed between 2013 and 2014. Demographic, virological, biochemical, and genetic characteristics of each patient were investigated. Liver fibrosis was assessed by transient elastometry. Mean age of the patients (72.9 % males, 27.1 % females) is 50 years. 91.5 % % of patients are Caucasian, 8.5 % African. In the patients with HCV1 and HCV4 a higher frequency of IL28B CT is observed with a prevalence of 52.1 and 61.8 % respectively. As regards ethnic group, African people have a prevalence of 35.5 % for CC, while Caucasians have a prevalence of 23.8 % for CC. In our cohort, IL28B polymorphism does not show significant differences among ethnic groups and in HCV1 and HCV4 genotypes. As described in literature, IL28B CC genotype is confirmed as predictor of sustained virological response in both Caucasians and Africans. A significant correlation between liver fibrosis and IL28B polymorphism emerges.

Entities:  

Keywords:  HCV chronic hepatitis; HCV1 and HCV4 genotypes; IL28B polymorphism

Mesh:

Substances:

Year:  2017        PMID: 27271956     DOI: 10.1007/s10903-016-0444-9

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  29 in total

Review 1.  Hepatitis C virus genotype 4 therapy: progress and challenges.

Authors:  Sanaa M Kamal
Journal:  Liver Int       Date:  2011-01       Impact factor: 5.828

2.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

Authors:  Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guergnon; Bertrand Nalpas; Nicolas Goossens; Lorenz Kuske; Beat Müllhaupt; Tillman Gerlach; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Stephan Regenass; Guenter Dollenmaier; Hans Hirsch; Gladys Martinetti; Meri Gorgiewski; Marc Bourlière; Thierry Poynard; Ioannis Theodorou; Laurent Abel; Stanislas Pol; Jean-François Dufour; Francesco Negro
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

3.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

4.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

5.  Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

Authors:  Pablo Barreiro; Juan Antonio Pineda; Norma Rallón; Susanna Naggie; Luz Martín-Carbonero; Karin Neukam; Antonio Rivero; José Miguel Benito; Antonio Caruz; Eugenia Vispo; Angela Camacho; José Medrano; John McHutchison; Vincent Soriano
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

6.  Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.

Authors:  Moutaz Derbala; Nasser Rizk; Fatima Shebl; Saad Alkaabi; Nazeeh Eldweik; Anil John; Manik Sharma; Rafie Yaqoob; Muneera Almohanadi; Mohammed Butt; Khaled Alejji
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 7.  The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

Authors:  Nabil Antaki; Antonio Craxi; Sanaa Kamal; Rami Moucari; Schalk Van der Merwe; Samir Haffar; Adrian Gadano; Nizar Zein; Ching Lung Lai; Jean-Michel Pawlotsky; E Jenny Heathcote; Geoffrey Dusheiko; Patrick Marcellin
Journal:  Liver Int       Date:  2009-12-10       Impact factor: 5.828

8.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

Review 9.  Update on epidemiology of HCV in Italy: focus on the Calabria Region.

Authors:  Nadia Marascio; Maria Liberto; Giorgio Barreca; Emilia Zicca; Angela Quirino; Angelo Lamberti; Giovanna Bianco; Giovanni Matera; Lorenzo Surace; Giuseppina Berardelli; Lidia Surace; Vincenzo De Maria; Francesca Giancotti; Rosa Leone; Vilma Villella; Salvatore Nisticò; Annelisa Borelli; Vincenzina Caruso; Massimo Calderazzo; Gianfranco Griffo; Rosanna Masciari; Pasquale Minchella; Lucio Cosco; Carmelo Laganà; Angela Oliva; Giuseppe Foti; Maria Fiorillo; Giuseppa Bocchiaro; Pasquale Surace; Anna Ciccaglione; Massimo Ciccozzi; Francesco Cesario; Carlo Torti; Alfredo Focà
Journal:  BMC Infect Dis       Date:  2014-09-05       Impact factor: 3.090

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  2 in total

1.  Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients.

Authors:  Zehra Öksüz; Enver Üçbilek; Mehmet Sami Serin; Serkan Yaraş; Gülhan Örekici Temel; Orhan Sezgin
Journal:  Arch Virol       Date:  2021-11-24       Impact factor: 2.574

2.  Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients.

Authors:  Seham Mahrous Zaki; Hanan Samir Ahmed; Monkez Motieh Yousif; Eman Mohamed Awad
Journal:  Trop Med Infect Dis       Date:  2022-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.